| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.anglifesciences.com | |
| Market Cap | 93.07 Cr. | |
| Enterprise Value(EV) | 156.87 Cr. | 2023-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -1.54 | Trailing Twelve Months Ending 2023-06 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-06 |
| Industry PE | 38.47 | Trailing Twelve Months Ending 2023-06 |
| Book Value / Share | 67.37 | Trailing Twelve Months Ending 2023-06 |
| Price to Book Value | 1.06 | Calculated using Price: 71.27 |
| Dividend Yield | 1.40 | Period Ending 2022-03 |
| No. of Shares Subscribed | 1.31 Cr. | 13,058,287 Shares |
| FaceValue | 10 | |
| About ANG Lifesciences India Ltd. | ||
| The company is ISO-9001:2008 certified and has the modern & sophisticated plant, equipments, technique and manpower. The planning and construction of plant has been done to conform to the regulatory requirements as per the norms of WHO G.M.P. and G.L.P. as per schedule-M (revised). They manufacture their products in compliance with GMP requirements. They have dedicated area, machinery, facilities and advanced equipments for manufacturing of B-Lactum & Non-B Lactum products as per GMP Norms. The production block provides appropriate personnel and material flow. As per GMP norms, all the production processes are documented and validated to establish the accuracy of the procedures and the control measures. The Company's production capacity is 700 Lakhs Pcs per annum on per shift basis. Their products include sterile dry powder vials for Anti Biotics, Anti Ulcerant, Gluco corticoid and Anti inflammatory, Anti malarial and Anesthetic. | ||
| 1 Day |
|
-0.53% |
| 1 Week |
|
-2.86% |
| 1 Month |
|
-6.38% |
| 3 Month |
|
+4.92% |
| 6 Month |
|
-7.50% |
| 1 Year |
|
-54.62% |
| 2 Year |
|
-72.13% |
| 5 Year |
|
+232.42% |
| 10 Year |
|
| 1 years | 2022-03 | |
| Return on Equity (%) | 48.13 | |
| Return on Capital Employed (%) | 39.14 | |
| Return on Assets (%) | 14.06 |
| Particulars | 2 years | 2022-03 Rs. Cr. | 2023-03* Rs. Cr. |
| Shh. Funds | 84 | 86 | |
| Non Curr. Liab. | 37 | 27 | |
| Curr. Liab. | 166 | 162 | |
| Minority Int. | |||
| Equity & Liab. | 287 | 276 | |
| Non Curr. Assets | 94 | 89 | |
| Curr. Assets | 193 | 187 | |
| Misc. Exp. not W/O | |||
| Total Assets | 287 | 276 |
| Particulars | 2 years | 2022-03 Rs. Cr. | 2023-06 Rs. Cr. TTM |
| Net Sales | 354 | 203 | |
| Other Income | 1 | 10 | |
| Total Income | 355 | 213 | |
| Total Expenditure | -286 | -194 | |
| PBIDT | 69 | 19 | |
| Interest | -9 | -11 | |
| Depreciation | -6 | -9 | |
| Taxation | -13 | 0 | |
| Exceptional Items | |||
| PAT | 40 | -2 | |
| Minority Interest | |||
| Share Associate | |||
| Other Related Items | |||
| Consolidated Net Profit | 40 | -2 | |
| Adjusted EPS | 31 | -2 |
| Particulars | 1 years | 2022-03 Rs. Cr. |
| Cash Fr. Operatn. | 25 | |
| Cash Fr. Inv. | -44 | |
| Cash Fr. Finan. | 20 | |
| Net Change | 0 | |
| Cash & Cash Eqvt | 0 |
|
Sat, 30 Sep 2023
Shareholder Meeting / Postal Ballot-Outcome of AGM Please find and enclosed herewith Outcome of AGM along with Summary of AGM proceeding for FY 2022-23. |
|
Wed, 27 Sep 2023
Closure of Trading Window Intimation of Closure of Trading window from 1st October 2023 till the disclosure of Unaudited Standalone & Consolidated Financial results for the half year and quarter ended 30th September 2023. |
|
Fri, 15 Sep 2023
Reg. 34 (1) Annual Report. Previously in cause of bulk file there has been some typographical error in the report therefore we enclosed the revised Annual Report for your reference. |
| Fri, 29 Sep 2023 |
High Decrease in 1 Month
|
High Decrease in 1 Year
|
High Decrease in 2 Years
|
High Increase in 5 Years
|
Closing Near 50 SMA
|
Equities
M.F.
Sectors
StockEdge Social